viewScancell Holdings PLC

Scancell receives European patent protection for immunotherapy platform

The patent protects a new class of cancer vaccines rolling off the Moditope platform

word patent spelled out in building blocks
The company is looking to extent patent protection internationally

Scancell Holdings PLC (LON:SCLP) said the European Patent Office has "granted broad protection" for the company's Moditope immunotherapy platform, which comes into effect from June 13.

It covers the company's pipeline of Moditope-derived vaccines. Counterparts to thpatent have been filed in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US, the firm added.

"This is a key patent for Scancell and endorses our work in identifying a new class of cancer vaccine capable of inducing potent immune responses to stress-induced post-translational modifications (siPTM), in this case, through citrullination of cellular proteins," said chief scietific officer,  Professor Lindy Durrant.

Well positioned

"We are now well positioned to develop a pipeline of new Moditope therapies with the potential to address the unmet need across a broad range of hard-to-treat cancers including ovarian, triple negative breast cancer and sarcoma."

First-in-man trials with Modi-1, which combines Moditope peptides with an ultra-efficient substance called an adjuvant that enhances the body's immune response, are due to start in the first half of next year.


Quick facts: Scancell Holdings PLC

Price: 12.875 GBX

Market: LSE
Market Cap: £81 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...


Scancell Holdings awarded funds from Innovate UK for COVID-19 vaccine

Scancell Holdings' (LON:SCLP) Dr Cliff Holloway talks to Proactive London's Katie Pilbeam after being awarded funds from Innovate UK to produce a COVID-19 vaccine. Holloway explains how the company is using their immunotherapies knowledge which is used in their cancer research projects to...

2 weeks, 4 days ago

2 min read